KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Other Operating Expenses (2016 - 2025)

Neogenomics (NEO) has disclosed Other Operating Expenses for 16 consecutive years, with $24.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses changed 0.1% year-over-year to $24.1 million, compared with a TTM value of $119.8 million through Dec 2025, up 34.69%, and an annual FY2025 reading of $119.8 million, up 41.47% over the prior year.
  • Other Operating Expenses was $24.1 million for Q4 2025 at Neogenomics, down from $28.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $44.1 million in Q2 2025 and bottomed at $13.7 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $20.5 million, with a median of $17.8 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses fell 0.89% in 2022, then soared 89.98% in 2025.
  • Year by year, Other Operating Expenses stood at $15.9 million in 2021, then grew by 7.7% to $17.1 million in 2022, then increased by 5.43% to $18.1 million in 2023, then soared by 33.06% to $24.0 million in 2024, then increased by 0.1% to $24.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for NEO at $24.1 million in Q4 2025, $28.9 million in Q3 2025, and $44.1 million in Q2 2025.